The antibody therapy developer closed a $100m round co-led by Lilly Asia Ventures that will fund phase 3 clinical studies for its lead drug candidates.
Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly, co-led a $100m funding round for China-based antibody drug developer RemeGen yesterday, DealStreetAsia reported.
The round was co-led by healthcare investment fund Lake Bleu Capital and included Vivo Capital, Janchor Partners, Hudson Bay Capital, OrbiMed, Loyal Valley Capital, Guoxin Guoxin Dongwu Overseas Fund and unnamed existing investors.
RemeGen is developing therapies based on antibody and fusion proteins, antibody-drug conjugates and bifunctional antibodies in order to fight diseases with…